IR TOPICS

Ajinomoto Co., Inc.

15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, Japan



June 15, 2023

Contributing to drug development with technological capabilities cultivated through years of amino acid research Ajinomoto Genexine Co., Ltd.'s biopharmaceutical culture media business

The Ajinomoto Group's culture media business has developed based on the "AminoScience" of amino acid bioprocessing, analysis, and evaluation technologies that we have cultivated since our founding.

Ajinomoto Genexine Co., Ltd. (South Korea) is using its current Good Manufacturing Practice (cGMP)-compliant culture media plant established in 2014 and its CELLiST™ Solution Center (CSC) established in 2019 as the core for developing its business. While strengthening connections with a wide range of customers around the world, we provide rapid and advanced culture media development and extensive technical support tailored to customer needs.

Expectations are growing for biopharmaceuticals, especially antibody drugs, because of their therapeutic effects on intractable diseases and minimal side effects. The Ajinomoto Group will support the development and manufacture of biopharmaceuticals through this culture media business and contribute to the delivery of pharmaceuticals to as many people as possible who need them.

This video introduces the development and manufacturing site of $CELLiST^{TM}$, Ajinomoto Genexine Co., Ltd.'s medium for biopharmaceutical use. Please take a look.



↓Please click on the image below to move to the video.

The Ajinomoto Group has "Contributing to the well-being of all human beings, our society, and our planet with 'AminoScience'" as its purpose. Based on this purpose, we are carrying out Ajinomoto Group Creating Shared Value (ASV), an initiative to create both economic and social value through our business. We will continue to make ASV the core of our business development to realize our purpose and enhance our corporate value.

Reference

Business briefing material, June 13, 2023, Growth Strategy for the Biopharmaceutical and Regenerative Medicine Culture Media Business

https://www.ajinomoto.co.jp/company/en/ir/event/business_briefing/main/01112/teaserItems1/01/linkList/01/link/4_Culture%20Media_E.pdf

Ajinomoto Genexine Co., Ltd. https://en.ajinomotogenexine.com/

The Ajinomoto Group will contribute to the well-being of all human beings, our society and our planet with "AminoScience" based on the corporate slogan "Eat Well, Live Well." The Ajinomoto Group has offices in 36 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2022, sales were 1.3591 trillion yen (10.0 billion U.S. dollars). To learn more, visit www.ajinomoto.com.

For further information, please contact:

Ajinomoto Co., Inc. Global Finance Dept. Investor Relations Group investor_relations@asv.ajinomoto.com